XTRA:BAYNPharmaceuticals
Bayer (XTRA:BAYN) Valuation Check As Twin FDA Priority Reviews Highlight Pipeline Progress
The key driver for Bayer (XTRA:BAYN) today is the FDA granting Priority Review to two investigational drugs: HYRNUO for certain HER2 mutated lung cancers, and asundexian for secondary stroke prevention, spotlighting its late stage pipeline.
See our latest analysis for Bayer.
That regulatory momentum comes after a weak patch for the stock, with the 30 day share price return down 6.28% and the 90 day share price return down 15.91%, even as the 1 year total shareholder return is 64.88%.
If this...